

Title (en)
ORAL DOSAGE FORM

Title (de)
ORALE DOSIERUNGSFORM

Title (fr)
FORME DE DOSAGE ORALE

Publication
EP 3141242 A3 20170621 (EN)

Application
EP 16188095 A 20160909

Priority
• EP 15184849 A 20150911
• EP 15193826 A 20151110

Abstract (en)
[origin: EP3141242A2] The present invention is in the field of delivering an active substance to the oral cavity and relates to mucoadhesive active composition and corresponding mucoadhesive dosage form, which can deliver an active substance within the oral cavity, especially an orodispersible tablet for delivering probiotic substance. The present invention also relates to a method of producing the said composition and a method of processing the composition into a mucoadhesive dosage form, especially an orodispersible tablet. The present invention moreover relates to a system and a method for testing the mucoadhesion of a dosage form.

IPC 8 full level
A61K 9/00 (2006.01); **A61K 9/16** (2006.01)

CPC (source: CN EP KR US)
A61K 9/0056 (2013.01 - CN EP KR US); **A61K 9/006** (2013.01 - EP KR US); **A61K 9/1635** (2013.01 - CN); **A61K 9/1652** (2013.01 - CN); **A61K 9/2009** (2013.01 - EP US); **A61K 9/2013** (2013.01 - EP US); **A61K 9/2018** (2013.01 - EP US); **A61K 9/2027** (2013.01 - CN EP US); **A61K 9/2045** (2013.01 - US); **A61K 9/205** (2013.01 - EP US); **A61K 9/2054** (2013.01 - CN EP US); **A61K 9/2059** (2013.01 - US); **A61K 9/2063** (2013.01 - EP US); **A61K 9/2068** (2013.01 - US); **A61K 9/2095** (2013.01 - US); **A61K 35/741** (2013.01 - CN KR); **A61K 35/747** (2013.01 - EP US); **A61K 47/32** (2013.01 - KR); **A61K 47/38** (2013.01 - KR); **G01N 19/04** (2013.01 - CN); **G01N 33/5088** (2013.01 - EP US); **A61K 9/19** (2013.01 - EP US); **A61K 2035/115** (2013.01 - EP US)

C-Set (source: EP US)
A61K 35/747 + A61K 2300/00

Citation (search report)
• [X] US 2011256229 A1 20111020 - NYSTROM CHRISTER [SE], et al
• [X] US 2011008493 A1 20110113 - ZOREA YOHAI [IL]
• [XD] US 2011028431 A1 20110203 - ZERBE HORST G [CA], et al
• [X] KLAYRAUNG S ET AL: "Development of tablets containing probiotics: Effects of formulation and processing parameters on bacterial viability", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 370, no. 1-2, 31 March 2009 (2009-03-31), pages 54 - 60, XP026001807, ISSN: 0378-5173, [retrieved on 20081118], DOI: 10.1016/J.IJPHARM.2008.11.004
• [A] FLÁVIA CHIVA CARVALHO ET AL: "Mucoadhesive drug delivery systems", BJPS BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 46, no. 1, 1 January 2010 (2010-01-01), Brazil, XP055333722, ISSN: 1984-8250, DOI: 10.1590/S1984-82502010000100002

Cited by
IT202100010802A1; WO2021212000A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
EP 3141242 A2 20170315; EP 3141242 A3 20170621; EP 3141242 B1 20240410; CA 2941464 A1 20170311; CN 106822007 A 20170613; CN 106822007 B 20211231; KR 20170035800 A 20170331; US 11033589 B2 20210615; US 2017071988 A1 20170316; US 2020078422 A1 20200312

DOCDB simple family (application)
EP 16188095 A 20160909; CA 2941464 A 20160909; CN 201610722937 A 20160825; KR 20160117373 A 20160912; US 201615261042 A 20160909; US 201916574402 A 20190918